Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants.

Hornik CP, Herring AH, Benjamin DK Jr, Capparelli EV, Kearns GL, van den Anker J, Cohen-Wolkowiez M, Clark RH, Smith PB; Best Pharmaceuticals for Children Act-Pediatric Trials Network.

Pediatr Infect Dis J. 2013 Jul;32(7):748-53. doi: 10.1097/INF.0b013e31828be70b.

2.

Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.

Nakane T, Tamura K, Hino M, Tamaki T, Yoshida I, Fukushima T, Tatsumi Y, Nakagawa Y, Hatanaka K, Takahashi T, Akiyama N, Tanimoto M, Ohyashiki K, Urabe A, Masaoka T, Kanamaru A; Japan Febrile Neutropenia Study Group.

J Infect Chemother. 2015 Jan;21(1):16-22. doi: 10.1016/j.jiac.2014.08.026. Epub 2014 Sep 17.

PMID:
25239059
3.
4.
5.

Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever.

Arnold HM, McKinnon PS, Augustin KM, Hladnik LM, Casabar E, Reichley RM, Dubberke ER, Westervelt P, Ritchie DJ.

Pharmacotherapy. 2009 Aug;29(8):914-23. doi: 10.1592/phco.29.8.914.

6.

Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.

Brismar B, Malmborg AS, Tunevall G, Lindgren V, Bergman L, Mentzing LO, Nyström PO, Anséhn S, Bäckstrand B, Skau T, et al.

J Antimicrob Chemother. 1995 Jan;35(1):139-48.

PMID:
7768761
7.

The risk of seizures among the carbapenems: a meta-analysis.

Cannon JP, Lee TA, Clark NM, Setlak P, Grim SA.

J Antimicrob Chemother. 2014 Aug;69(8):2043-55. doi: 10.1093/jac/dku111. Epub 2014 Apr 16.

PMID:
24744302
8.

Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.

Kuo BI, Fung CP, Liu CY.

Zhonghua Yi Xue Za Zhi (Taipei). 2000 May;63(5):361-7.

PMID:
10862445
10.

A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections.

Hou F, Li J, Wu G, Zheng B, Chen Y, Gu J, Wang H, Huo L, Xue X, Jia C, Yin Y, Tian X, Ren S.

Chin Med J (Engl). 2002 Dec;115(12):1849-54.

PMID:
12622937
11.

Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.

Bartoloni A, Strohmeyer M, Corti G, Buonomini MI, Franchino L, Romanelli G, Moretti AM, De Vizzi GB, Petraglia A, Mancini P, Atzeni R, Fogliani V, Giura R, Paradisi F.

Drugs Exp Clin Res. 1999;25(6):243-52.

PMID:
10713862
12.

Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections.

Garau J, Blanquer J, Cobo L, Corcia S, Daguerre M, de Latorre FJ, León C, Del Nogal F, Net A, Rello J.

Eur J Clin Microbiol Infect Dis. 1997 Nov;16(11):789-96.

PMID:
9447899
14.

Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.

Fournier A, Eggimann P, Pagani JL, Revelly JP, Decosterd LA, Marchetti O, Pannatier A, Voirol P, Que YA.

Burns. 2015 Aug;41(5):956-68. doi: 10.1016/j.burns.2015.01.001. Epub 2015 Feb 10.

PMID:
25678084
15.

[Tolerance and safety of carbapenems: the use of meropenem].

Lizasoaín M, Noriega AR.

Enferm Infecc Microbiol Clin. 1997 Sep;15 Suppl 1:73-7. Review. Spanish.

PMID:
9410074
16.
17.

Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections.

Nichols RL, Smith JW, Geckler RW, Wilson SE.

South Med J. 1995 Apr;88(4):397-404. Erratum in: South Med J 1995 Jun;88(6):634.

PMID:
7716590
18.

Carbapenems in serious infections: a risk-benefit assessment.

Norrby SR.

Drug Saf. 2000 Mar;22(3):191-4. Review.

PMID:
10738843
20.

Is it safe to use carbapenems in patients with a history of allergy to penicillin?

Sodhi M, Axtell SS, Callahan J, Shekar R.

J Antimicrob Chemother. 2004 Dec;54(6):1155-7. Epub 2004 Oct 14.

PMID:
15486083

Supplemental Content

Support Center